Olesya Evgen'EVna Danilova

Olesya Evgen'EVna Danilova

Auto-generated profile, based on publicly available information

Olesya Evgen'EVna Danilova

Samara State Medical University, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2020 in Russian Open Medical Journal
Verified
Journal Article
Closed access
IDIgor L. Davydkin
Igor L. Davydkin
TKTatyana P. Kuzmina
Tatyana P. Kuzmina
KNKsenia V. Naumova
Ksenia V. Naumova
RKRais K. Khayretdinov
Rais K. Khayretdinov
ODOlesya E. Danilova
Olesya E. Danilova
EMElizaveta V. Mordvinova
Elizaveta V. Mordvinova
The article is dedicated to contemporary views on the change of endothelial function in the patients with lymphoproliferative disorders prior to, and in the process of, chemotherapeutic treatment. Considering that possibilities of standard examination do not always help identifying subclinical endothelial dysfunction, it is necessary to use specific methods, in particular, to determine the levels of endothelin-1 and vascular endothelial growth factor to monitor endothelial function. The objective of this review is to identify problems and prospects for recognizing early subclinical changes of endothelial function in the patients with lymphoproliferative disorders before and after chemotherapy. Assessing presence and severity of endothelial dysfunction may be useful for determining subclinical stages of cardiovascular damage, stratifying the risk of the patients with confirmed cardiovascular disease, and reducing the likelihood of cardio- and endotheliotoxic effects in patients long after chemotherapy. That is why early detection and immediate therapy of cardiovascular toxicity is currently the most important task in the patients with lymphoproliferative disorders, receiving chemotherapy.

30 March 2023 in Ulyanovsk Medico-biological Journal
Verified
Journal Article
Closed access
LRLarisa Aleksandrovna Rogozina
Larisa Aleksandrovna Rogozina
IDIgor' Leonidovich Davydkin
Igor' Leonidovich Davydkin
OFOleg Veniaminovich Fatenkov
Oleg Veniaminovich Fatenkov
ODOlesya Evgen'EVna Danilova
Olesya Evgen'EVna Danilova
RKRais Kettdusovich Khayretdinov
Rais Kettdusovich Khayretdinov
GGGeliya Rifkatovna Gimatdinova
Geliya Rifkatovna Gimatdinova
Atypical hemolytic uremic syndrome (aHUS) is a systemic disease, a type of thrombotic microangiopathy (TMA). It is based on uncontrolled activation of the alternative complement pathway of a hereditary or acquired nature, leading to generalized thrombosis in the microvasculature. Chronic activation of the alternative complement pathway leads to the damage of endothelial cells, erythrocytes and platelets and, as a result, to thrombotic microangiopathy and systemic multiorgan damage. Currently, in roughly half of the cases, it is impossible to identify aHUS triggers. Fresh frozen plasma (FFP) is used as first-line drug to reverse the symptoms. It helps to eliminate the deficiency of self-proteins – complement factor H and complement factor I (CFH and CFI), membrane cofactor protein (MCP), and stable and labile proteins – factors of hemostasis, and to stop thrombosis in the microvasculature. FFP administration is a preparatory step before anticomplementary therapy. Disease prognosis is always serious and is associated with severe complications and high mortality. At least 6 % of patients develop multiple organ failure with generalized TMA, injury of the central nervous system, gastrointestinal tract, lungs, and kidneys. The paper describes a clinical case of a patient with aHUS.

11 March 2020 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
IDI. L. Davydkin
I. L. Davydkin
ТКТ. П. Кузьмина
Т. П. Кузьмина
IZI. A. Zolotovskaya
I. A. Zolotovskaya
OTO. V. Tereshina
O. V. Tereshina
ODO. E. Danilova
O. E. Danilova
LRL. A. Rogozina
L. A. Rogozina
Aim. To assess eft ventricular (LV) contractility dysfunction in patients with chronic lymphocytic leukemia (CLL) receiving chemotherapy with fludarabine, cyclophosphamide, and rituximab (FCR), and to determine the enalapril.effectiveness for their treatment.Material and methods. The study included 49 patients with newly diagnosed Binet stage B CLL in combination with class I-II stable angina, stage 1-2 hypertension and LV ejection fraction (EF) >50%. All subjects did not take angiotensin converting enzyme inhibitors (ACE inhibitors), had no clinical signs of heart failure (HF), and all had indications for FCR combination use before study start. Patients underwent two-dimensional echocardiography initially, before starting chemotherapy (period V1) and after three (84±5 days) (V2) and six (168±7 days) (V3) courses of chemo therapy (enalapril) was added to the treatment regimen in the experimental group.Results. After the third course of chemotherapy, a relative percentage decrease in global longitudinal strain (GLS) was noted in the experimental and control groups — by 16,16±0,80 and 16,2±0,79, respectively (p=0,764). These changes are considered a cardiotoxicity predictor. At the same time, LVEF values remained within the normal range: 63,4% [65; 68] in the experimental group and 63,9% [61,6; 67] in the control group (p=0,960). After the sixth course, LVEF values significantly differed (p=0,002): in the control group, five patients (21%) had cardiotoxicity; in experimental group, there were no patients with cardiotoxicity.Conclusion. A clinically significant decrease in GLS is a marker of subclinical LV contractile dysfunction and is a cardiotoxicity predictor in CLL patients receiving chemotherapy with FCR. The timely addition of enalapril to the treatment regimen can prevent cardiotoxicity in such patients. The need for early assessment of GLS during FCR courses for the detection and prevention of cardiotoxicity has been proved.

29 January 2024 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
GGG. R. Gimatdinova
G. R. Gimatdinova
ODO. E. Danilova
O. E. Danilova
IDI. L. Davydkin
I. L. Davydkin
HJHunan Julhakyan
Hunan Julhakyan
EUE. V. Usenko
E. V. Usenko
Aim. To study the possibilities of instrumental research methods in relation to the earliest detection of cardiovascular events in oncohematological patients receiving antitumor immunochemotherapy, as well as to deter­mine the requirements for documenting adverse events.Material and methods. For the study, 63 patients were prospectively selected with a diagnosis of indolent non-Hodgkin lymphoma, who were indicated for antitumor immunochemotherapy. The patients were examined in three stages (before treatment, after 3 and 6 cycles of therapy) and divided into 2 groups by simple randomization. Cardiovascular toxicity in the main group of patients was assessed using 3D transthoracic echocardiography, analysis of left ventricular (LV) global longitudinal systolic strain and electrocardiography. The control group underwent a standard 3D echocardiography with analysis of LV ejection fraction. Clinical manifestations of cardiovascular events were assessed in all patients during treatment.Results. According to the study, significant changes were obtained in LV ejection fraction on the third visit — a decrease from 58,9±1,07 to 48,1±0,73% (p<0,05) and from 57,7±1,13 to 49,4±0,58% (p<0,05) in patients of the main and control groups and global longitudinal LV strain from |21,1±1,18 to |14,0±1,61 |% (p<0,05) in patients of the main group. A mixed clinical phenotype of cardiovascular toxicity was the most common among all patients. An integrated approach to the early diagnosis of cardiovascular events makes it possible to identify a larger percentage of patients with subclinical myocardial dysfunction.Conclusion. The long period of latent cardiovascular toxicity emphasizes the need for early verification of cardiovascular complications of antitumor therapy and expansion of the established paraclinical diagnostic minimum. In addition, taking into account the accumulated experience, recommendations are presented for the preparation of medical documentation in order to ensure the safety and quality of care.


14 September 2022 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
GGG. R. Gimatdinova
G. R. Gimatdinova
ODO. E. Danilova
O. E. Danilova
IDI. L. Davydkin
I. L. Davydkin
RKR. K. Khairetdinov
R. K. Khairetdinov
AAA. V. Antipova
A. V. Antipova
The review analyzes the global agenda on mutational status of genes associated with adverse cardiovascular events of arrhythmic type. Whole exome sequencing will identify a risk group for the likelihood of early or delayed cardiovascular events of arrhythmic type, especially among patients receiving anticancer therapy with cardiotoxic drugs. The dedicated up-to-date panel of genetic polymorphisms will provide an opportunity to optimize management of patients, based on not only clinical, paraclinical and anamnestic data.